Brompheniramine


Brompheniramine, sold under the brand name Dimetapp among others, is an antihistamine drug of the propylamine class. It is readily available over the counter and is indicated for the treatment of the symptoms of the common cold and allergic rhinitis, such as runny nose, itchy eyes, watery eyes, and sneezing. It is a first-generation antihistamine and one of the drugs of highest anticholinergic activity.
It was patented in 1948 and came into medical use in 1955.

Side effects

Brompheniramine's effects on the cholinergic system may include side-effects such as drowsiness, sedation, dry mouth, dry throat, blurred vision, and increased heart rate. It is listed as one of the drugs of highest anticholinergic activity in a study of anticholinergenic burden, including long-term cognitive impairment.

Pharmacology

Brompheniramine works by acting as an antagonist of histamine H1 receptors. It also functions as a moderately effective anticholinergic agent, and is likely an antimuscarinic agent similar to other common antihistamines such as diphenhydramine.
Brompheniramine is metabolised by cytochrome P450s.
The halogenated alkylamine antihistamines all exhibit optic isomerism and brompheniramine products contain racaemic brompheniramine maleate whereas dexbrompheniramine is the dextrorotary stereoisomer.

Chemistry

Brompheniramine is part of a series of antihistamines including pheniramine and its halogenated derivatives and others including fluorpheniramine, chlorpheniramine, dexchlorpheniramine, triprolidine, and iodopheniramine. The halogenated alkylamine antihistamines all exhibit optical isomerism and brompheniramine products contain racemic brompheniramine maleate whereas dexbrompheniramine is the dextrorotary stereoisomer.
Brompheniramine is an analog of chlorpheniramine. The only difference is that the chlorine atom in the benzene ring is replaced with a bromine atom. It is also synthesized in an analogous manner.

History

Based on this knowledge, Arvid Carlsson
and his colleagues, working at the Swedish company Astra AB, were able to derive the first marketed selective serotonin reuptake inhibitor, zimelidine, from brompheniramine.

Names

Brand names include Bromfed, Dimetapp, Bromfenex, Dimetane, BPN, Lodrane. It is commonly marketed as its salt brompheniramine maleate.